QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
QuidelOrtho Corp
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026
$12.76−0.15 (-1.16%)
Close on Oct 19, 2026
- Market cap
- $871.51M
- P/E (TTM)
- –
- Dividend yield
- –
QuidelOrtho Corp revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $327.40M | $328.90M | $390.10M | $381.40M | $310.70M | $406.70M | $399.60M | $436.20M | $350.10M | $433.90M | $450.30M | $465.20M | 51.9% | +5.4% |
| EMEA | $91.20M | $92.50M | $92.70M | $91.80M | $87.30M | $88.90M | $85.90M | $84.00M | $81.10M | $84.80M | $90.90M | $74.50M | 14.5% | +4.5% |
| JPAC | $74.30M | $70.00M | – | – | $72.20M | $68.10M | – | – | – | – | – | – | 11.8% | +2.9% |
| Latin America | $70.20M | $64.90M | – | – | $60.30M | $54.10M | – | – | – | – | – | – | 11.1% | +16.4% |
| China | $67.80M | $63.50M | $91.70M | $84.60M | $83.40M | $75.00M | $86.90M | $80.40M | $81.60M | $76.10M | – | – | 10.7% | -18.7% |
| China | – | – | – | – | – | – | – | $80.40M | $81.60M | $76.10M | $77.10M | $81.10M | – | – |
| Other | – | – | – | – | – | – | – | $126.50M | $124.20M | $116.20M | $124.30M | $123.20M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of QuidelOrtho's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.